New symmetrical acyclic and alicyclic bisureaderivatives of 4,4'-methylenebis(phenyl isocyanate): Synthesis, characterization, bioactivity and antioxidant activity evaluation and molecular docking studies
Among the compounds 10e, 10f, 10g, 10k,10l and 10m showed very good binding energies which implied that they could be promising next generation antimicrobials.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:A family of bisurea derivatives of 4,4′-methylenebis(phenyl isocyanate) have been synthesized with simple, effective and efficient procedure in high yields.
📊
Key Findings & Data:The new compounds showed moderate bioactivity (at 32.0 μ g/μ L concentration) against selected bacterial pathogens, viz., Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa; and two fungal species, Candida albicans and Cryptococcus neoformans var. grubii.
💡
Conclusion & Impact:Among the compounds 10e, 10f, 10g, 10k,10l and 10m showed very good binding energies which implied that they could be promising next generation antimicrobials.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
A family of bisurea derivatives of 4,4′-methylenebis(phenyl isocyanate) have been synthesized with simple, effective and efficient procedure in high yields. The new compounds showed moderate bioactivity (at 32.0 μ g/μ L concentration) against selected bacterial pathogens, viz., Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa; and two fungal species, Candida albicans and Cryptococcus neoformans var. grubii. Alternatively, their antioxidant activity was also evaluated by DPPH radical scavenging assay which revealed that the compounds, 10d, 10e, 10h and 10m exhibited moderate activity. However, the molecular docking studies of all the title compounds showed surprisingly higher binding energies with DNA gyrase A protein of E. coli when compared to the reference, streptomycin. Among the compounds 10e, 10f, 10g, 10k,10l and 10m showed very good binding energies which implied that they could be promising next generation antimicrobials.
🔖
Cite This Article
CHAMARTHİ, N. R., PONNE, V. C., PULLURU, H. B., BALİJA, J. D., GUTALA, S. R., KALLİMAKULA, S. V., CHİNTHA, V., WUDAYAGİRİ, R. (2018). New symmetrical acyclic and alicyclic bisureaderivatives of 4,4'-methylenebis(phenyl isocyanate): Synthesis, characterization, bioactivity and antioxidant activity evaluation and molecular docking studies. Organic Communications, Cilt: 11 - Sayı: 2, 80–97. https://ajindex.com/articles/288484
Keiji Fukuda. Antimicrobial Resistance: Global Report on Surveillance 2014. 2014. [2]Christopher, T.W.; Timothy, A.W. Prospects for new antibiotics: a molecule-centered perspective. J. Antibiot.2014, 67, 7-22. [3]Liao-Bin, D.; Jeffrey, D.R.; Ben, S. Antibacterial sulfur-containing platensimycin and platencin congeners from Streptomyces platensis SB12029. Bioorg. Med. Chem.2016, 24, 6348-6353. [4]Sheo B. S. Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase. Bioorg. Med. Chem.2016, 24, 6291-6297. [5]Lyn P.N.D. Lead toxicity. A review of the literature. Part I: Exposure, evaluation and treatment. Alternat. Med. Rev.2006, 11, 1, 2-22. [6]Ronald, L.P.; Xianli, W.; Karen, S. Standardized methods for the determination of antioxidant capacityand phenolics in foods and dietary supplements. J. Agric. Food Chem.2005, 53, 4290-4302. [7]Lyn P.N.D. Lead toxicity part II: The role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Alternat. Med. Rev.2006, 11, 2, 114-127. [8]a)Thomas, C.G.; George, S. A critical appraisal of the evolution of N-Nitrosoureas as anticancer drugs. Chem. Rev.1997,97, 829 -1013; b) Zijian, L.; Yu, W.; Huafang, L.; Dazhuang, Z.; Lihui, W.; Yanfang, Z.; Ping, G. Design, synthesis and biological evaluation of novel thieno[3,2-d] pyrimidine derivativescontaining diaryl urea moiety as potent antitumor agents. Eur. J. Med. Chem.2014, 85, 215-227. [9]a)Yu, Z.; Jiang, W.; Zhanni, G.; Shuni, W.; Wei, Z.; José, L.A.; Vadim, A.S.; Kunisuke, I.; Hong, L. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II−III clinical trials of major pharmaceutical companies: New structural trends and therapeutic areas. Chem. Rev.2016, 116, 422-518; b) Xiaobing, C.; Bojian, X.; Liang, C.; Feng, Z.; Beibei, C.; Huifang, L.; Xingxing, F.; Lili, H.; Liangyu, B.; Xinguang, C.; Xiaokun, S.; Feilin, C. Direct binding of microRNA-21 pre-element with Regorafenib: Analternative mechanism for anti-colorectal cancer chemotherapy? J. Mol. Graph. Model.2017, 73, 48-53. [10]Marta, S.; Jerzy, K.; Ewa, K.D.; Sylwia, F.; Joanna, S.S. Synthesis and pharmaco-logical activity of urea and thiourea derivatives of 4-Azatricyclo [5.2.2.02,6]undec-8-ene-3,5-dione. Chem. Pharm. Bull.2007, 55, 796-799. [11]Chinnasamy, R.P.; Sundararajan, R. Design, synthesis and antiepileptic properties of novel 1-(substituted benzy